AZTA vs. FOLD, ARWR, IMCR, TXG, AMED, GDRX, PGNY, LTH, JANX, and IDYA
Should you be buying Azenta stock or one of its competitors? The main competitors of Azenta include Amicus Therapeutics (FOLD), Arrowhead Pharmaceuticals (ARWR), Immunocore (IMCR), 10x Genomics (TXG), Amedisys (AMED), GoodRx (GDRX), Progyny (PGNY), Life Time Group (LTH), Janux Therapeutics (JANX), and IDEAYA Biosciences (IDYA). These companies are all part of the "medical" sector.
Amicus Therapeutics (NASDAQ:FOLD) and Azenta (NASDAQ:AZTA) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, community ranking, dividends, media sentiment, valuation, analyst recommendations and profitability.
99.1% of Azenta shares are owned by institutional investors. 2.2% of Amicus Therapeutics shares are owned by company insiders. Comparatively, 1.8% of Azenta shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Amicus Therapeutics presently has a consensus price target of $18.40, indicating a potential upside of 101.75%. Azenta has a consensus price target of $68.40, indicating a potential upside of 30.51%. Given Azenta's stronger consensus rating and higher possible upside, analysts plainly believe Amicus Therapeutics is more favorable than Azenta.
Amicus Therapeutics received 496 more outperform votes than Azenta when rated by MarketBeat users. Likewise, 73.47% of users gave Amicus Therapeutics an outperform vote while only 39.58% of users gave Azenta an outperform vote.
Azenta has higher revenue and earnings than Amicus Therapeutics. Azenta is trading at a lower price-to-earnings ratio than Amicus Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Amicus Therapeutics had 4 more articles in the media than Azenta. MarketBeat recorded 25 mentions for Amicus Therapeutics and 21 mentions for Azenta. Amicus Therapeutics' average media sentiment score of 0.51 beat Azenta's score of 0.25 indicating that Azenta is being referred to more favorably in the news media.
Azenta has a net margin of -23.12% compared to Azenta's net margin of -34.73%. Amicus Therapeutics' return on equity of 0.81% beat Azenta's return on equity.
Amicus Therapeutics has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500. Comparatively, Azenta has a beta of 1.51, indicating that its share price is 51% more volatile than the S&P 500.
Summary
Amicus Therapeutics beats Azenta on 10 of the 18 factors compared between the two stocks.
Get Azenta News Delivered to You Automatically
Sign up to receive the latest news and ratings for AZTA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AZTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
